Global Parkinson’s Genetics Program Data Release 7
By onIn December 2025, GP2 announced the 11th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 20,842 additional genotyped participants, 17,153 additional WGS participants, and 4,232 additional clinical exomes. - The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 103,786 genotyped participants (46,327 PD cases, 28,857 Controls, and 28,602 ‘Other’ phenotypes). - The whole genome sequencing (WGS) data now consists of a total of 38,226 sequenced participants (18,219 PD cases, 9,172 Controls, and 10,835 ‘Other’ phenotypes). - The clinical exome data now consists of 14,648 samples with PD. - Of the 122,317 unique samples with genetic data (NBA, WGS, or clinical exome), 32,897 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.17753486, release 11) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."
Global Parkinson’s Genetics Program Data Release 8
By onIn September 2024, GP2 announced the eighth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 5,481 additional whole genome sequences and 10,454 clinical exome sequences. Additional genotyping will be provided in the following release. - The whole genome sequencing (WGS) data now consists of a total of 7,734 sequenced participants (6,113 PD cases, 617 Controls, and 1,004 ‘Other’ phenotypes). - Additionally, included in this WGS release is a partial release of whole genome sequences from two AMP® PD cohorts (BioFind and PPMI) that have been joint-called with GP2 WGS. Released samples can be linked back to the original AMP® PD IDs through an ID crosswalk file included with the release. - This release also includes 10,454 joint-called clinical exome sequencing participants from the Parkinson’s Foundation. - This release includes a total of 62,087 individuals who have core clinical data available. Among these, 16,800 individuals have deep clinical phenotyping and genetic data available. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.10962119, release 8) used in the preparation of this article were obtained from the Global Parkinson’s Genetics Program (GP2)."
Global Parkinson’s Genetics Program Data Release 9
By onIn December 2024, GP2 announced the 9th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 17,690 additional genotyped participants. The genotype array data, including locally-restricted samples, now consists of a total of 71,835 genotyped participants (31,985 PD cases, 18,249 Controls, and 21,601 ‘Other’ phenotypes) When removing the locally-restricted samples, these now consist of 55,305 samples (23,709 PD cases, 13,404 Controls, and 18,192 ‘Other’ phenotypes) Of those 71,835 samples with genotyped data: 16,800 individuals also have deep clinical phenotyping information (Release 8) 10,454 total individuals also have clinical exomes information (Release 8) 7,732 total individuals also have WGS data (Release 8) Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.14510099, release 9) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."
Global Parkinson’s Genetics Program Data Release 10
By onIn July 2025, GP2 announced the 10th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 11,109 additional genotyped participants and 13,339 additional WGS participants. The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 82,944 genotyped participants (36,939 PD cases, 19,821 Controls, and 26,184 ‘Other’ phenotypes). When removing the locally-restricted samples, these now consist of 65,303 samples (28,586 PD cases, 15,258 Controls, and 21,459 ‘Other’ phenotypes). The whole genome sequencing (WGS) data now consists of a total of 21,073 sequenced participants (8,134 PD cases, 3,531 Controls, and 9,408 ‘Other’ phenotypes). When removing the locally-restricted samples, these now consist of 16,608 participants (6,801 PD cases, 3,244 Controls, and 6,563 ‘Other’ phenotypes). Of note, cases recruited via the Monogenic network are coded as ‘Other’. The clinical exome data now consists of 10,454 samples with PD (Release 8). Of the 92,021 unique samples with genetic data (NBA, WGS, or clinical exome), 26,982 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.15748014, release 10) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."
Global Parkinson’s Genetics Program Data Release 11
By onIn December 2025, GP2 announced the 11th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 20,842 additional genotyped participants, 17,153 additional WGS participants, and 4,232 additional clinical exomes. - The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 103,786 genotyped participants (46,327 PD cases, 28,857 Controls, and 28,602 ‘Other’ phenotypes). - The whole genome sequencing (WGS) data now consists of a total of 38,226 sequenced participants (18,219 PD cases, 9,172 Controls, and 10,835 ‘Other’ phenotypes). - The clinical exome data now consists of 14,648 samples with PD. - Of the 122,317 unique samples with genetic data (NBA, WGS, or clinical exome), 32,897 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.17753486, release 11) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."
Metagenomics sequencing data of publication doi.org/10.3389/fnins.2025.1546203
By onThe study explores the connection between *GBA1* gene variants and gut microbiome in a mouse model, shedding light on Parkinson's disease development.
MSP abundance table associated with doi.org/10.3389/fnins.2025.1546203
By onSummary: The table displays the abundance of microbial species in the gut of GBA1 L444P/WT mouse model, exploring the connection between GBA1 host genotype and gut microbiome in Parkinson's disease research.
Read Alignment table associated with doi.org/10.3389/fnins.2025.1546203
By onSummary: The publication explores the link between the *GBA1* host genotype and gut microbiome in the *GBA1*L444P/WT mouse model, shedding light on Parkinson's disease development.
Data and code for shotgun metagenomics associated with Moiseyenko et al. 2025
By onData and scripts to retrieve and analyze shotgun metagenomic data of wild-type, Thy1-ASO, and Faecalibacterium prausnitzii-treated Thy1-ASO mice from Moiseyenko et al. (2025)
Fecal metagenomic sequencing data for PD patients and controls from Rush University Medical Center
By onFecal metagenomic sequencing data associated with Boktor et al. (2023). This dataset includes samples from the Rush University Medical Center cohort.
Global Parkinson’s Genetics Program Data Release 5
By onThis release includes 7,462 additional new complex disease participants and 487 new monogenic disease participants, adding to the previous releases from the Complex and Monogenic Networks. The complex disease data (genotypes) now consists of a total of 24,935 genotyped participants (12,728 PD cases, 10,533 Controls, and 1,674 ‘Other’ phenotypes). The monogenic disease data (whole genome sequences) now consists of a total of 722 sequenced participants. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.7904832, release 5) used in the preparation of this article were obtained from the Global Parkinson’s Genetics Program (GP2)."
Highly efficient generation of isogenic pluripotent stem cell models using prime editing – Datasets
By onThis collection contains the following datasets related to the paper Highly efficient generation of isogenic pluripotent stem cell models using prime editing 1. AAVS1 knock-in genotyping 2. aCGH karyotyping 3. Tabular datasets for associated graphical figures
Time to LiD GWAS dataset
By onCode to perform the study of LiD genetic determinants under CPH regression models and functional annotation analyses
Genome-wide determinants of mortality and clinical progression in Parkinson’s disease – Summary statistics
By onSummary statistics from "Genome-wide determinants of mortality and clinical progression in Parkinson’s disease."
Fecal metagenomic sequencing data for PD patients and controls from the BioCollective
By onFecal metagenomic sequencing data associated with Boktor et al. (2023). This dataset includes samples from the BioCollective cohort.
Bulk NGS/allele quantification – Highly efficient generation of isogenic pluripotent stem cell models using prime editing
By onThis file contains sequencing results for amplicons covering specific regions of interest related to prime editing of hPSCs
Temporal landscape of mitochondrial proteostasis governed by the UPRmt_NGS data_Part 1
By onNGS data associated with Uoselis et al., 2023.
Temporal landscape of mitochondrial proteostasis governed by the UPRmt_NGS data_Part 2
By onPart 2 of NGS data associated with Uoselis et al., 2023.
Next-generation sequencing of AAV.CAP-Mac enrichment from Chuapoco et al. (2023)
By onDataset of next-generation sequencing of enrichment of AAV.CAP-Mac in various tissues from the publication: Chuapoco, M.R., Flytzanis, N.C., Goeden, N. et al. Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain. Nat. Nanotechnol. (2023). https://doi.org/10.1038/s41565-023-01419-x
Saliva metagenomic data related to “Evaluation of an Adapted Semi-Automated DNA Extraction for Human Salivary Shotgun Metagenomics”
By onIn this study, we proposed a semi-automated DNA extraction protocol for human salivary samples collected with a commercial kit, and compared the outcomes with the DNA extraction recommended by the manufacturer. This study demonstrates that our semi-automated protocol is suitable for shotgun metagenomic analysis, by significantly producing higher DNA fragment sizes, while allowing for improved sample treatment logistics with reduced technical variability and without compromising the structure of the oral microbiome.
